logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Trick or Trade

Alterity Therapeutics: Treating Neurodegenerative Diseases?

When a small firm’s stock price soars, and more than doubles, curiosity pushes us to investigate.    Alterity Therapeutics Yesterday the stock soared for a firm called Alterity Therapeutics ( ATHE )  closing at $3.43 UP $2.08. We found that...

Read More

August 5, 2020

0

Monopar Therapeutics: A Plan for a Test that Predicts COVID-19 Patients Who Might Likely Develop Severe Respiratory Failure

A Predictive COVID-19 Test? COVID-19 infected people are not all affected to the same degree with regards to the severity of the disease complications. There is no doubt that a test that can predict which patients will be severely affected...

Read More

August 13, 2020

0

An Important Announcement from Sorrento Therapeutics

Sorrento Therapeutics Announcement Sorrento Therapeutics ( SRNE ) announced that it believes it has uncovered fraudulent attempts to manipulate the Company’s stock.  In a press release from August 12, 2020 Sorrento informed that, on August 11, 2020 it was reported...

Read More

August 13, 2020

0

The U.S. FDA Accepts Exelixis sNDA of CABOMETYX® for Priority Review

Exelixis sNDA Accepted by the US FDA for CABOMETYX ® The U.S. Food and Drug Administration ( FDA ) accepted Exelixis ( EXEL ) supplemental New Drug Application ( sNDA ) for CABOMETYX ® (cabozantinib) as a treatment for patients...

Read More

August 6, 2021

0

The FDA's Complete Response Letters, Creating Investment Opportunities?

Yesterday, under Today’s Highlights , we posted that the U.S. FDA issued a Complete Response Letter ( CRL ) to Gilead Sciences ( GILD ) with regard to the New Drug Application ( NDA ) for filgotinib - the investigational...

Read More

August 20, 2020

0

What's Going on with Gene Therapy?

Recent Gene Therapy News On August 20, 2020 Audentes Therapeutics , which was taken over by Astellas ( ALPMY ) for over $3 billion, announced that a third patient has passed away in a clinical trial evaluating its gene therapy...

Read More

August 25, 2020

0

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus ( AGEN ) immuno-oncology company announced that data from two Phase 2 trials of balstilimab alone and in combination with zalifrelimab will be orally presented in at the upcoming European Society...

Read More

September 2, 2020

0

Devastated and Resurrected Good Biotech Firms: Theravance Biopharma

The Market Devastation and Resurrection of Good Biotech Firms Due to the market’s instability that we have been experiencing for a while now, we decided to look back at some biotech firms whose values tumbled and stocks tanked as a...

Read More

December 15, 2021

0

Gain Therapeutics: A Biotech with Promising Treatments for Neurodegenerative Diseases and a Note from Prohost Biotech

Gain Therapeutics Inc in the News Gain Therapeutics, Inc. ( GANX ) announced today topline data from its  study conducted at the University of Maryland School of Medicine (UMSOM). The study, evaluating two lead Structurally Targeted Allosteric Regulators ( STARs...

Read More

September 8, 2021

0

Why Jounce Therapeutics Stock is Outperforming Today

Jounce Therapeutics Jounce Therapeutics ( JNCE ) is a clinical-stage immunotherapy company developing therapies enabling the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce has ongoing multiple development stage programs while simultaneously...

Read More

September 14, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 6
  • 7
  • 8
  • ...
  • 16
  • 17
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy